AU716519B2 - Method of treating renal disease using an ace inhibitor and an A II antagonist - Google Patents

Method of treating renal disease using an ace inhibitor and an A II antagonist Download PDF

Info

Publication number
AU716519B2
AU716519B2 AU62916/96A AU6291696A AU716519B2 AU 716519 B2 AU716519 B2 AU 716519B2 AU 62916/96 A AU62916/96 A AU 62916/96A AU 6291696 A AU6291696 A AU 6291696A AU 716519 B2 AU716519 B2 AU 716519B2
Authority
AU
Australia
Prior art keywords
lisinopril
losartan
recited
ace inhibitor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62916/96A
Other languages
English (en)
Other versions
AU6291696A (en
Inventor
Ronald S. Eydelloth
Roger A. Owen
Giuseppe Remuzzi
Shahnaz Shahinfar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Original Assignee
Laboratories Merck Sharp and Dohme Chibret SAS
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602854.3A external-priority patent/GB9602854D0/en
Application filed by Laboratories Merck Sharp and Dohme Chibret SAS, Merck and Co Inc filed Critical Laboratories Merck Sharp and Dohme Chibret SAS
Publication of AU6291696A publication Critical patent/AU6291696A/en
Application granted granted Critical
Publication of AU716519B2 publication Critical patent/AU716519B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU62916/96A 1995-06-30 1996-06-26 Method of treating renal disease using an ace inhibitor and an A II antagonist Ceased AU716519B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77095P 1995-06-30 1995-06-30
US60/000770 1995-06-30
GBGB9602854.3A GB9602854D0 (en) 1996-02-13 1996-02-13 Method of treating renal disease using an ace inhibitor and an II antagonist
GB9602854 1996-02-13
PCT/US1996/010942 WO1997002032A1 (en) 1995-06-30 1996-06-26 Method of treating renal disease using an ace inhibitor and an aii antagonist

Publications (2)

Publication Number Publication Date
AU6291696A AU6291696A (en) 1997-02-05
AU716519B2 true AU716519B2 (en) 2000-02-24

Family

ID=26308665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62916/96A Ceased AU716519B2 (en) 1995-06-30 1996-06-26 Method of treating renal disease using an ace inhibitor and an A II antagonist

Country Status (5)

Country Link
EP (1) EP0835106A4 (de)
JP (1) JPH11508894A (de)
AU (1) AU716519B2 (de)
CA (1) CA2224451A1 (de)
WO (1) WO1997002032A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
EP1326604A2 (de) * 2000-04-12 2003-07-16 Novartis AG Kombination von mindestens 2 aus einer at1-rezeptoren-antagonist- oder einer ace-inhibitor- oder einer hmg-co-a reduktase inhibitorgruppe selektierte wirkstoffe
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
JP2004520268A (ja) * 2000-08-22 2004-07-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アンギオテンシンｉｉ拮抗剤とアンギオテンシンｉ変換酵素阻害剤とを含有する医薬組成物
ES2309187T3 (es) * 2001-08-31 2008-12-16 Australian Biomedical Company Pty Ltd Preparacion y uso de giberelinas para tratar la diabetes.
EP1438027A1 (de) 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
EP1452176A4 (de) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Mittel zur verbesserung der insulinresistenz
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
US20060217421A1 (en) * 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
PT2800738T (pt) 2012-01-06 2020-06-23 Novartis Ag Compostos heterocíclicos e métodos para a utilização dos mesmos
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
CA2079982A1 (en) * 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
CA2224451A1 (en) 1997-01-23
EP0835106A4 (de) 1998-09-30
AU6291696A (en) 1997-02-05
EP0835106A1 (de) 1998-04-15
WO1997002032A1 (en) 1997-01-23
JPH11508894A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
JP4843172B2 (ja) 医薬処方物および卒中、糖尿病および／またはうっ血性心不全の予防におけるその使用
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
AU2001295465B2 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
PT2086535E (pt) Antagonista do receptor de angiotensina ii para o tratamento de doenças sistémicas em gatos
Melian et al. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension
AU2001295465A1 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
CN102256488A (zh) 伴随代谢失衡慢性肾病的治疗组合物和治疗方法
AU2013345494B2 (en) 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CA2515941A1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
ZA200106022B (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction.
EP2157089A1 (de) Therapeutische anwendungen von imidazol-5-carbonsäurederivaten
AU2013336293B2 (en) Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy
Yasunari et al. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile
TWI281858B (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
CN110292637B (zh) 一种预防、治疗高血压的药物组合物
CN103037861A (zh) 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途
JP5958772B2 (ja) 腎障害の治療又は予防薬
KR20040054665A (ko) 지방이영양증의 치료
Sica Newer Antihypertensive Agents
Hudyono Renin inhibitor in hypertension treatment: from pharmacological point of view
Lisy et al. O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP
Adam et al. O-33: Omapatrilat (OMA) a vasopeptidase inhibitor prevents mortality and cardiovascular injury in salt sensitive hypertension in addition to but independent of blood pressure
WO2005039638A2 (en) Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired